Microneedle patch releases immunotherapy directly into melanoma tumors

A 'dirty bomb' against cancer

Bacterium with Expanded Genetic Alphabet Produces Novel Protein

Diagnostic test 'Odoreader' detects prostate cancer

The sensor for the diagnosis of prostate cancer (lat. Prostate Carcinoma) by urine was developed by scientists from the University of Liverpool and the University of the West of England. Prostate cancer is one of the most common oncological diseases among men. The success of its treatment depends heavily on the stage at which it was diagnosed. And this is the main problem because men do not like to see a doctor until the disease crosses the line when it becomes very important for life. Unfortunately, then it may be too late. The development of simple methods for diagnosing cancer will greatly help to solve this problem. The main aim of scientists is to create a test that avoids procedure of detecting cancer in a non-invasive way by smelling the disease in men’s urine.

by
15 hours ago

A new nanobiochip can diagnose and monitor prostate cancer at early stages

Developing low-cost and highly efficient nanobiochips are important for liquid biopsies, real-time monitoring, and precision medicine. Therefore, the scientific group from the Chinese Academy of Sciences in collaboration with the University of Chinese Academy of Sciences, and the Peking University Third Hospital has developed a cost-effective device that operates like Velcro® to capture prostate cancer cells on frosted glass slides, allowing the easy diagnosis. The innovative sensor traps prostate cancer (lat. Carcinoma) cells on a modified frosted glass slide, therefore, allowing medicals to perform fast and simple diagnoses and monitoring of the disease.

by
15 hours ago

Innovative peptides as targeted therapies for oncology

Molecules that fight cancer (lat. Carcinoma) were developed by PEP-Therapy. The company manages Cell Penetrating and Interfering (CP & IP) peptide technology to develop its therapeutic products. These innovative molecules penetrate the cells, and then specifically block the corresponding intracellular protein interactions, thereby inhibiting the key pathological mechanisms. PEP-Therapy is based on the research results of the Inserm (French National Institutes of Health), the Institut Curie (the largest French research and hospital center dedicated to cancer research) and the University of Sorbonne (formerly Pierre and Marie Curie University of Paris, UPMC, university).

by
15 hours ago

In Vivo PA Imaging of Liver will provide the effective liver cancer diagnosis

3D printed implant for patients with bone cancer

'Azeria' provides the new way to treat people with cancer

The novel treatment will be able to overcome cancer

The new technology for treating cancer (lat. Carcinoma) and other human diseases was developed by Twentyeight-Seven Therapeutics. The company is focused on the modulation of functional non-coding RNA (ncRNA). By targeting ncRNA modulating proteins (RMPs), inventors can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company’s core technology comes from its four founding scientists, all leading researchers in RNA biology and cancer from Harvard Medical School, namely, George Daley, M.D., Ph.D., Richard Gregory, Ph.D., Frank Slack, Ph.D. and Piotr Sliz, Ph.D. An unexpected discovery made by the scientists is that ninety-eight percent of the human genome does not code for proteins. Rather, a significant portion of the genome produces non-coding RNAs (ncRNAs). Intensive research over the past decade has revealed that ncRNAs have critical functions in the regulation of nearly all biological processes.

by
15 hours ago

The breakthrough technology of producing humanized monoclonal antibodies

Antibody engineering services for all stages of therapeutic and diagnostic antibody development were developed by Fusion Antibodies. The company is spinoff from Queen's University. Unrivaled experience of the scientists in the medical research industry makes Fusion Antibodies first choice for development of antibodies for both therapeutic drug and diagnostic applications. The company mission is to enable biopharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. The company’s antibody engineering technology assists in the development of novel biological molecules that are used as innovative drugs for human diseases including cancer (lat. Carcinoma), coeliac disease, chronic fungal infections and immunological indications.

by
15 hours ago

EMcision’s medical devices for cancer treatment

The new device to treat cancer (lat. Carcinoma) of the liver, pancreas and bile ducts was developed by EMcision Ltd. The company is spinoff of Imperial College London, was founded by Professor Nagy Habib, Professor of Hepatobiliary Surgery in the Department of Surgery and Cancer at Imperial College London. EMcision develops innovative devices. Those products can help patients suffering from cancers. EMcision’s flagship product, the HabibTM EndoHPB, was the world’s first endoscopic device for tumor ablation via ERCP using radiofrequency energy in patients with advanced and inoperable pancreatic cancer and cholangiocarcinoma.

by
15 hours ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 VENTURE CLIENT PLATFORM